{"id":793078,"date":"2024-12-06T08:37:41","date_gmt":"2024-12-06T13:37:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kellner-group-urges-stockholders-of-aim-immunotech-to-vote-the-gold-card-2\/"},"modified":"2024-12-06T08:37:41","modified_gmt":"2024-12-06T13:37:41","slug":"kellner-group-urges-stockholders-of-aim-immunotech-to-vote-the-gold-card-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kellner-group-urges-stockholders-of-aim-immunotech-to-vote-the-gold-card-2\/","title":{"rendered":"Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card"},"content":{"rendered":"
\n

\n
\n ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency<\/em>
\n <\/strong>\n <\/p>\n

\n
\n According to ISS \u2013 \u201c<\/em>
\n <\/strong>
\n
\n
\n There is no question that for shareholders to have any hope of not losing 100 percent of their investment, significant change is needed<\/u>
\n <\/em>
\n <\/strong>
\n
\n \u201d<\/em>
\n <\/strong>
\n
\n
\n 1<\/em>
\n <\/strong>
\n <\/sup>\n <\/p>\n

\n
\n ISS Recommends to Vote on the Kellner Group\u2019s GOLD Card for Ted Kellner and Paul Sweeney<\/em>
\n <\/strong>\n <\/p>\n

\n
\n ISS Recommends Against Votes for Thomas Equels and Stewart Appelrouth<\/em>
\n <\/strong>\n <\/p>\n

\n
\n ISS Further States \u2013 \u201c<\/em>
\n <\/strong>
\n
\n
\n Equels<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n appears<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n to<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n be<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n the<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n most<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n directly<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n responsible<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n for<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n the<\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n company’s <\/u>
\n <\/em>
\n <\/strong>
\n
\n
\n failings<\/u>
\n <\/em>
\n <\/strong>
\n \u201d<\/em>
\n
\n
\n 2<\/em>
\n <\/strong>
\n <\/sup>\n <\/p>\n

\n
\n Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Kellner Group has Clear Plan to Stabilize AIM and Create Value <\/em>
\n <\/strong>\n <\/p>\n

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) — Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the \u201cKellner Group,\u201d \u201cwe\u201d or \u201cus\u201d and, as nominees, the \u201cKellner Group Nominees\u201d) today issue the following press release in connection with their efforts to bring accountability to the entrenched, incumbent Board of Directors of AIM Immunotech Inc. (NYSE American: AIM).<\/p>\n

\n
\n Leading Independent Proxy Advisory Firm Noted Massive Failures under Incumbent Board and Need for Significant Change<\/em>
\n <\/strong>\n <\/p>\n

Institutional Shareholder Services Inc. (\u201cISS\u201d), a leading independent proxy advisory firm, noted the following in its report:3<\/sup><\/p>\n